ArticleDermatology and therapy2025
Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.Acta dermato-venereologica · 2026Article
- Tildrakizumab in the Treatment of Complex and Severe Psoriasis: A Case Series.Journal of clinical medicine · 2026Article
- Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.Dermatology and therapy · 2026Article
- Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes.Journal of clinical medicine · 2026Article
- Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).Pharmacy (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-driven inflammatory condition that affects millions of people worldwide. Biologics appeared in the recent years to offer an effective treatment for moderate-to-severe plaque psoriasis. Their efficacy, however, is influenced by patient characteristics, such as obesity, disease severity or prior failure to biologic therapy. This review focuses on the current management of moderate-to-severe plaque psoriasis using tildrakizumab, the only interleukin-23p19 inhibitor offering two dosing options (100 mg or 200 mg) according to individual patient characteristics (high disease burden/body weight). It examines clinical data on the efficacy and effectiveness of both doses and identifies patient profiles that benefit most from tildrakizumab 100 mg or 200 mg. The manuscript also presents practical recommendations to help dermatologists individualize treatment, particularly guiding the appropriate use of the 200 mg dose in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.